about
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endotheliumHypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarkerExcess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humansSoluble endoglin contributes to the pathogenesis of preeclampsiaSoluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsiaMapping the theories of preeclampsia and the role of angiogenic factors: a systematic reviewWT1-dependent sulfatase expression maintains the normal glomerular filtration barrierLow-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary eliminationVitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study.Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy.Molecular mechanisms of preeclampsia.Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia.The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal diseaseRecombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension.Welles et al. respond to "Low vitamin D and cardiovascular disease"First-trimester follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus.Angiogenic dysfunction in molar pregnancy.Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality.Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancyPreeclampsia and the risk of large-for-gestational-age infants.New developments in the pathogenesis of preeclampsiaEndostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1.Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery.Carbon monoxide prevents hypertension and proteinuria in an adenovirus sFlt-1 preeclampsia-like mouse model.Breathing life into the lifecourse approach: pregnancy history and cardiovascular disease in women.Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF-1α pathway.Protein carbamylation in kidney disease: pathogenesis and clinical implicationsPlasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsiaTranscriptional patterns in peritoneal tissue of encapsulating peritoneal sclerosis, a complication of chronic peritoneal dialysis.First trimester PAPP-A levels correlate with sFlt-1 levels longitudinally in pregnant women with and without preeclampsia.Circulating angiogenic and antiangiogenic factors in women with eclampsia.Angiogenic factors and preeclampsia.Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules.Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.Midpregnancy levels of angiogenic markers in relation to maternal characteristics.Preeclampsia and the Anti-Angiogenic StateCellular actions and signaling by endostatin.Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease.
P50
Q24311749-BEC1B30F-EE1E-4FEC-86A3-BFE03E5259EEQ24595773-6E71941B-6613-4360-AE09-80F87A02F3B6Q25255098-87663CCA-1C6D-4C60-ADD3-7B0153C30916Q28244053-E265A5A7-0EDB-433F-86FE-6B299E95FF4FQ28244090-D89D6A33-F02E-4BB3-BB57-B95C27844CDEQ28281326-D1F7215D-6B70-4FBE-BC06-A08BADD99388Q28506573-98F14AFD-C538-441B-9FA1-7F926D250E2FQ28538906-D5790D0C-F40C-4158-AA69-D56E9EFA3B88Q30793329-F41AABF8-F804-4B5E-90CB-80D6343333CEQ33275899-D9730A8C-C8FD-4A74-80B0-EB888D186559Q33344105-28601556-2501-498F-AFA5-D6AEAF4A93F9Q33349183-3DC2C486-F953-484C-8387-A838EBA2A714Q33385942-EE5319CB-0BD6-4481-8318-685C1C2EE3DBQ33423350-540194A2-2DB3-4E31-A3E3-3E8E70FD376BQ33532601-BA85A640-0A92-48D3-8350-E7B5008FBA31Q33666742-97C37D26-0808-463A-8C6D-C3814C366C96Q33675979-6D208363-A62F-43E7-92DF-F92E9D9DB23EQ33683820-BD4E42BA-8D15-4750-922B-A4B477D41A1AQ33703272-022FD50B-A32F-4D58-ACE6-7887AF573700Q33850993-736484CC-B3E9-49EA-9706-98AE2963CAB0Q33893203-7E5832E2-9E58-462C-8BB3-6A93E9ABD2E5Q33924175-97EC9840-1745-4A05-9DC1-5BE2FA6A0826Q33935675-62107D04-373F-42F9-9E49-4590AE2A1493Q34111700-D91DC27F-91FF-4569-9854-2CD300F94210Q34116772-82598973-0A4E-4451-9076-3A7C3A3E3073Q34155902-A124BEDC-11E7-4499-8555-7435DA72BE09Q34169172-86274B05-811A-486B-9706-32464FE59037Q34365552-498AB8C5-F1E4-471D-BCAD-0F664E20FFD6Q34403945-E322ADA4-7781-4451-A125-5031249A057DQ34461130-7E74573F-04D6-44D3-8589-16E62E3623BEQ34590067-F280C184-763C-4593-AF8A-225103EAFA03Q34655258-322AB80A-2379-4029-B67D-E642EAFDEC74Q34670638-6F92D3F5-FC66-4421-91F7-77B6D9223771Q34714082-617184F7-26E4-4624-BD67-8618D6FA57CEQ34775094-D74F7173-A71D-4765-80CF-A22CE63B11B4Q34803030-9448E8AD-5E3B-4589-B3E4-AD5739E8637FQ34821237-CD629BED-6CC8-4E36-A219-401DC5387A09Q34920271-5CB99527-8F3A-41D0-9C76-E4E21C304CF6Q35008096-5F3A2651-E770-4655-9CC4-84425F45AE9DQ35143007-765921A8-CB47-4116-A338-8DEB096FEDFA
P50
name
S Ananth Karumanchi
@ast
S Ananth Karumanchi
@en
S Ananth Karumanchi
@nl
type
label
S Ananth Karumanchi
@ast
S Ananth Karumanchi
@en
S Ananth Karumanchi
@nl
prefLabel
S Ananth Karumanchi
@ast
S Ananth Karumanchi
@en
S Ananth Karumanchi
@nl
P214
P214
P31
P7859
lccn-n2009182695